REGENXBIO Inc. (RGNX)
| Market Cap | 489.85M +44.7% |
| Revenue (ttm) | 170.44M +104.5% |
| Net Income | -193.88M |
| EPS | -3.76 |
| Shares Out | 51.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 454,365 |
| Open | 9.49 |
| Previous Close | 9.19 |
| Day's Range | 9.28 - 9.62 |
| 52-Week Range | 5.85 - 16.19 |
| Beta | 1.13 |
| Analysts | Strong Buy |
| Price Target | 28.75 (+202.95%) |
| Earnings Date | May 11, 2026 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12... [Read more]
Financial Performance
In 2025, REGENXBIO's revenue was $170.44 million, an increase of 104.54% compared to the previous year's $83.33 million. Losses were -$193.88 million, -14.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RGNX stock is "Strong Buy." The 12-month stock price target is $28.75, which is an increase of 202.95% from the latest price.
News
SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD
Notice to Pension Funds, Asset Managers, and Fiduciaries NEW YORK, March 26, 2026 /PRNewswire/ -- Institutional investors holding positions in REGENXBIO, Inc. (NASDAQ: RGNX) during the period between ...
Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals
Regenxbio Inc. (NASDAQ: RGNX) shares are down on Wednesday after the company reported new interim data from its Phase 1/2 AFFINITY DUCHENNE trial of RGX-202.
Regenxbio's Duchenne gene therapy shows improved muscle function in trial
Regenxbio said on Wednesday that an interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued improvement ...
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional measures at 1 ye...
FDA reversals leave investors worrying about the fates of other experimental drugs
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing co...
RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST
Promise vs. Reality: The REGENXBIO Gene Therapy Performance Gap NEW YORK, March 5, 2026 /PRNewswire/ -- "Very promising results.
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected earl...
REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
ROCKVILLE, Md., March 4, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its RGX-202 investigational gene therapy for Duchenne muscular dystrophy at the 2026 Muscul...
REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses
SAN DIEGO, March 2, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) se...
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., March 2, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Leerink Partners Global Healthcare Conference Fir...
REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
ROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO Lawsuit - RGNX
NEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX). Shareholders who purchased shares of RGNX during the class peri...
FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment
In May 2025, the FDA accepted the RGX-121 BLA under the accelerated approval pathway; however, the Prescription Drug User Fee Act (PDUFA) goal date was extended from November 9, 2025, to February 8, 2...
US FDA declines to approve Regenxbio's rare disease drug
Regenxbio said on Monday the U.S. Food and Drug Administration has declined to approve its drug for a rare disease.
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
FDA issues Complete Response Letter for RGX-121 (clemidsogene lanparvovec) for treatment of Mucopolysaccharidosis II (MPS II) REGENXBIO plans to work with FDA on a path forward with the goal of resubm...
RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $RGNX--RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm.
Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action
(NASDAQ: RGNX) NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Regenxbio Inc. (NASDAQ: RGNX) regarding potential gaps between information provided to investors and under...
FDA Clinical Hold Knocks REGENXBIO Stock
REGENXBIO Inc. (NASDAQ: RGNX) shares are tumbling on Wednesday with a session volume of 3.83 million versus an average volume of 684.271 thousand.
US FDA places clinical hold on Regenxbio's gene therapy trials
Regenxbio said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its experimental gene therapy programs for rare childhood diseases after a brain tumor was found ...
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
ROCKVILLE, Md., Jan. 28, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy,...
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect at pivotal dose at 18 months Robust patient enrollment in confirmatory trial continues, expect majority of pati...
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. , Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44th Annual J.P.
REGENXBIO to Participate in Upcoming Investor Conference
ROCKVILLE, Md. , Nov. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Conference F...
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial enrollment completed in October; confirmatory trial ...
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
Patients treated with RGX-202 demonstrate consistent, robust microdystrophin expression and functional improvement compared to natural history in Phase I/II portion of AFFINITY DUCHENNE® trial support...